Literature DB >> 31684733

Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer.

Swaroop Revannasiddaiah1, Ishu Gupta2, Santhosh Kumar Devadas2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31684733     DOI: 10.21037/cco.2019.01.07

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


× No keyword cloud information.
  2 in total

1.  Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis.

Authors:  Runtian Luo; Yongbo Chen; Ke Ran; Qing Jiang
Journal:  Transl Androl Urol       Date:  2020-12

2.  MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.

Authors:  Meng Jiao; Facai Zhang; Wei Teng; Chengjun Zhou
Journal:  Int J Gen Med       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.